Reddy E K
Br J Cancer Suppl. 1978 Jun;3:250-4.
A majority of previous studies have shown the effectiveness of nitroimidazole derivatives, metronidazole and Ro-07-0582, in specifically sensitizing the hypoxic cell componenet of solid tumours to single doses of irradiation. The present study investigated the effects of nitroimadazoel Ro-07-0582 (0.75 mg/g) on the growth of MNU fibrosarcoma when administered with fractionated radiation therapy. Delay of tumour regrowth was recorded and was compared to single dose experiments using the sensitizer. The results show that fractionated radiotherapy with the sensitizer has an advantage over fractionated therapy alone (delay factor 1.58), but not over single dose therapy with the sensitizer (delay factor 2.6). This difference may be due to the sublethal repair from re-oxygenation in fractionated radiotherapy.
此前的大多数研究表明，硝基咪唑衍生物、甲硝唑和Ro-07-0582能有效使实体瘤的缺氧细胞成分对单次照射敏感。本研究调查了硝基咪唑Ro-07-0582（0.75毫克/克）与分次放射治疗联合使用时对MNU纤维肉瘤生长的影响。记录了肿瘤再生长的延迟情况，并与使用该敏化剂的单剂量实验进行比较。结果表明，使用敏化剂的分次放射治疗比单纯的分次治疗具有优势（延迟因子为1.58），但并不优于使用敏化剂的单剂量治疗（延迟因子为2.6）。这种差异可能是由于分次放射治疗中再充氧引起的亚致死性修复。
